Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces supply agreement with U.S.

Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna’s stock has rallied almost 4x since the beginning of this year, rising from levels of about $20 to near $75 currently. However, we believe the vaccine, if successful, is only likely to contribute meaningfully to Moderna’s earnings for about two years, after which the rest of the company’s.

What Will Moderna Look Like Post Covid-19?

Moderna fell sharply after briefly trading close to $100.

Why Moderna Is Moving Nowhere For Now

AstraZeneca

BioNTech SE

Inovio Pharmaceuticals

Merck

Novavax

Pfizer

COVID-19 has weakened the US economy more than China's.

T Cell Responses To Coronavirus Vaccines Are In The Interest Of National Security

CAMBRIDGE, Mass.--(BUSINESS WIRE)--John Lepore joins Moderna as Senior Vice President, Government Engagement.

John Lepore Joins Moderna as Senior Vice President, Government Engagement

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Johnson & Johnson

Eli Lilly

Novo Nordisk

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.

Biotech's Q2:  Lots Of Candidates That May Deliver Alpha

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) has struck its first deal with a government agency, as Switzerland confirmed Friday reports of procuring the mRNA vaccine developed by the company against SARS-CoV-2, Reuters reported.

Moderna Signs Deal With Swiss Government To Supply 4.5M Doses Of Coronavirus Vaccine

Amid chatter that Moderna's Inc (NASDAQ: MRNA) investigational coronavirus vaccine is pricier relative to rivals, the company offered some clarity on pricing on its earnings call.

Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing

Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.

Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates

Clinical trial data and progress in the coronavirus vaccine program drove the shares higher.

Why Moderna Stock Rose 15.4% in July

Pharmaceutical company Moderna is at the forefront of the global race to develop a vaccine against Covid-19. We could know as early as October whether Moderna's vaccine will be given the green light from regulators, and the company is already scaling up production to meet demand.

As a Vaccine Looks More Likely, Moderna Stock Still Is a Good Bet

The biotech got a little help from Amazon's AWS.

How Moderna Went From Coronavirus Sequence to a Phase-1-Ready Vaccine Candidate in 42 Days

Disney

Roku

Block

A Roku earnings preview, along with Disney, Square and Moderna were our top stock trades from Wednesday. That said, let's look at the charts.

4 Top Stock Trades for Thursday: DIS, SQ, ROKU, MRNA

Before the market opened on Aug. 5, Moderna Inc. (NASDAQ:MRNA) reported its earnings results for the second quarter.

Moderna: A Strong Quarter, but No Miracle Cure Yet

Moderna, Inc. (MRNA) CEO Stéphane Bancel on Q2 2020 Results - Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), announced that Moderna, Inc.

AWS Powers Moderna’s Digital Biotechnology Platform to Develop New Class of Vaccines and Therapeutics

Moderna Inc (NASDAQ: MRNA) shares were moving to the downside Wednesday despite the coronavirus vaccine developer reporting forecast-beating second-quarter results and reports of a potential deal with the Swiss government.

Moderna Posts Q2 Beat, Reportedly Closes In On Coronavirus Vaccine Deal With Swiss Government

Moderna Inc. (NASDAQ: MRNA) published its quarterly financial results on Wednesday that came in significantly stronger than what the experts had forecast.

Moderna’s revenue jumps over 400% in the fiscal second quarter

The vaccine maker has received about $400 million in deposits from various countries for potential supply.

Moderna Plans To Charge $32-37 Per Covid Vaccine Dose, Discussing Supply Deals With Several Countries

Moderna, one of the companies working on a treatment for Covid-19, said Wednesday that it's on track to finish enrollment for a phase 3 study of its vaccine by the end of September.

Moderna already got $400 million for a Covid vaccine that isn't available

Moderna is charging between $32 to $37 per dose for its coronavirus vaccine for some customers, under cheaper “pandemic pricing,” the company said.

Moderna is pricing coronavirus vaccine at $32 to $37 per dose for some customers

Shares of Moderna (NASDAQ:MRNA) moved higher by 0.7% in pre-market trading after the company reported Q2 results.

Recap: Moderna Q2 Earnings

Shares of Moderna Inc. MRNA, +0.61% gained 1.9% in premarket trading on Wednesday after the company said it plans to complete enrollment for the Phase 3 trial for its COVID-19 vaccine candidate in September and that it has already received $400 million in deposits in preparation of the experimental vaccine's regulatory authorization.

Moderna's stock rallies as it moves forward with enrolling its Phase 3 COVID-19 vaccine trial

Moderna Inc said on Wednesday it has started talks with several countries for supply agreements for its experimental coronavirus vaccine and has received about $400 million in deposits for potential supply.

Moderna says discussing supply deals with countries for COVID-19 vaccine

The coronavirus vaccine maker reported a smaller-than-expected loss as surged crushed views. MRNA stock rose early Wednesday.

News for Moderna Stock (MRNA)